Promising results with the decrease in esophageal eosinophilia and EoE symptoms were observed after the use of dupilumab—anti Il-4 and monoclonal antibody blocking Il-13 (RPC4046) [104]. This evidence concerns the gene IL13 and eosinophilic esophagitis.